Back

Cannabis Use by People with HIV is Associated with an Anti-Inflammatory Immunometabolic Phenotype in Monocyte-Derived Macrophages

Ford, M.; Halcrow, P. W.; Laird, A.; Leyva, B.; Boustani, A.; Spencer, M.; Melcher, J.; Walter, K.; Hong, D.; Funk, G.; Searson, E.; Le, A. A.; Ellis, R. J.; Letendre, S.; Marcondes, M. C. G.; Schlachetzki, J.; Iudicello, J.; Fields, J. A.

2026-03-06 immunology
10.64898/2026.03.04.709579 bioRxiv
Show abstract

Chronic neuroinflammation is associated with comorbidities in people with HIV (PWH) on antiretroviral therapy (ART). While cannabis use is associated with reduced neuroinflammation and neurocognitive impairment (NCI) in PWH, the underlying mechanisms are unknown. To address this gap in knowledge, we analyzed monocyte-derived macrophages (MDMs) from a cohort of 50 PWH and 33 people without HIV (mean age: 61.9 years), categorized by frequency of cannabis use (naive/low, moderate, daily). We performed immunocytochemistry, RNA sequencing, and qPCR on MDMs and quantified related biomarkers in donor plasma. In this cohort study, daily cannabis use in PWH was associated with less global neurocognitive deficits, and with an anti-inflammatory immunometabolic-phenotype in MDMs characterized by (1) a metabolic shift from glycolysis to oxidative phosphorylation, (2) higher mitochondrial numbers, (3) altered cytokine profiles (pro-inflammatory downregulation, anti-inflammatory upregulation), and (4) higher brain-derived neurotrophic factor (BDNF) expression. These cellular changes were corroborated by a plasma biomarker profile in PWH including (1) lower levels of growth differentiation factor 15 and soluble triggering receptor expressed on myeloid cells 2, and (2) higher mature BDNF/precursor BDNF ratios that correlated with better cognition. Thus, cannabis use may mitigate NCI in PWH by immunometabolically reprogramming MDM function towards an anti-inflammatory and neuroprotective state. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=140 SRC="FIGDIR/small/709579v1_ufig1.gif" ALT="Figure 1"> View larger version (42K): org.highwire.dtl.DTLVardef@15fb1adorg.highwire.dtl.DTLVardef@189d79corg.highwire.dtl.DTLVardef@aa6a89org.highwire.dtl.DTLVardef@3852f8_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

1
AIDS
31 papers in training set
Top 0.1%
26.7%
2
Brain, Behavior, and Immunity
105 papers in training set
Top 0.1%
23.3%
50% of probability mass above
3
Neuroscience & Biobehavioral Reviews
43 papers in training set
Top 0.1%
6.6%
4
Journal of Neuroinflammation
50 papers in training set
Top 0.1%
4.3%
5
Neuropsychopharmacology
134 papers in training set
Top 0.8%
3.7%
6
eLife
5422 papers in training set
Top 24%
3.7%
7
Molecular Psychiatry
242 papers in training set
Top 1%
2.8%
8
The Journal of Infectious Diseases
182 papers in training set
Top 2%
1.9%
9
Frontiers in Immunology
586 papers in training set
Top 4%
1.7%
10
Communications Biology
886 papers in training set
Top 8%
1.7%
11
eBioMedicine
130 papers in training set
Top 2%
1.1%
12
Brain, Behavior, & Immunity - Health
27 papers in training set
Top 0.3%
1.1%
13
iScience
1063 papers in training set
Top 24%
1.0%
14
Viruses
318 papers in training set
Top 5%
0.8%
15
Cell Reports
1338 papers in training set
Top 31%
0.8%
16
Scientific Reports
3102 papers in training set
Top 74%
0.8%
17
Nature Communications
4913 papers in training set
Top 65%
0.7%
18
Advanced Science
249 papers in training set
Top 21%
0.7%
19
Stem Cell Reports
118 papers in training set
Top 1%
0.5%
20
Frontiers in Psychiatry
83 papers in training set
Top 4%
0.5%
21
Frontiers in Cellular Neuroscience
79 papers in training set
Top 2%
0.5%
22
Clinical Epigenetics
53 papers in training set
Top 1%
0.5%
23
Neuropharmacology
60 papers in training set
Top 0.8%
0.5%